Compare DSP & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | NKTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 247.4M |
| IPO Year | 2021 | 2020 |
| Metric | DSP | NKTX |
|---|---|---|
| Price | $10.60 | $2.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $17.81 | $11.33 |
| AVG Volume (30 Days) | 179.7K | ★ 948.3K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | 11.88 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $344,201,000.00 | N/A |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $16.88 | N/A |
| P/E Ratio | $29.56 | ★ N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $8.11 | $1.63 |
| 52 Week High | $16.25 | $3.65 |
| Indicator | DSP | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 49.46 |
| Support Level | $8.49 | $1.88 |
| Resistance Level | $10.73 | $2.66 |
| Average True Range (ATR) | 0.69 | 0.27 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 39.36 | 32.57 |
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.